The health of Advanced Cell Technology (ACT) is still, I think, a fair barometer of support and funding for embryonic stem cell research. The latest from UPI: "Advanced Cell Technology said Friday it has closed two financings generating approximately $13 million in cash. ... ACT said it would also use the proceeds toward three therapeutic programs that the company said it hopes to bring to clinical trials, including therapies to treat degenerative eye disease, heart and vascular disease, and technology to regenerate skin damaged by wounds, burns and in surgical procedures." It seems that private investors have decided there is now little risk of US politicians criminalizing therapeutic cloning or otherwise directly suppressing freedom of research in ways that would impact companies like ACT.

View the Article Under Discussion: http://www.upi.com/HealthBusiness/view.php?StoryID=20060908-112800-1450r
Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/